Eli Lilly and Boehringer Ingelheim’s Jardiance has become the first diabetes drug to show a significant reduction in cardiovascular deaths in a dedicated outcomes study. According to data* from the 7,000-plus patient trial EMPA-REG OUTCOME, Jardiance (empagliflozin) cut the risk of cardiovascular death by 38% when added to standard of care in type II diabetics
New data from the Phase IIIb OTEMTO 1&2 trials show Spiolto Respimat provides consistent and clinically meaningful improvements in quality of life versus placebo in patients with chronic obstructive pulmonary disease (COPD).
We are acting as a functional provider for Boehringer Ingelheim – and therefore we are the only recruitment company offering the Clinical Trial Administrator (CTA) roles. Boehringer Ingelheim is one of the top 20 leading pharmaceutical companies in the world, with 699 of their 46,000 employees from the UK. Working with Boehringer Ingelheim is therefore
Patients in the UK with type II diabetes now have access to a new alternative for managing their blood glucose levels with the launch of Boehringer Ingelheim/Eli Lilly’s new combination drug, Jentadueto, being launched in the UK this week. Jentadueto combines two antiglycaemic therapies – the veteran drug metformin with the dipeptidyl peptidase (DPP)-IV inhibitor
Boehringer Ingelheim announced earlier today that they have submitted their first oncology compound, afatinib, to European regulators. The German firm filed a marketing authorisation application to the European Medicines Agency (EMA) for the approval of afatinib as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Boehringer confirmed that afatinib
European regulators have given approval to Boehringer Ingelheim and Eli Lilly’s diabetes combo drug, Jentadueto. The pharmaceutical organisations announced earlier today that they received marketing authorisation from the European Commission (EC) for Jentadueto, which combines metformin with the dipeptidyl peptidase (DPP)-IV inhibitor Trajenta (linagliptin) in a single pill. The approval was expected after the European
Final draft guidance released from the UK’s National Institute for Health and Clinical Excellence (NICE) recommends the use of Boehringer Ingelheim’s Pradaxa (dabigatran) for the prevention of stroke and systemic embolism in people with atrial fibrillation. In addition, the draft guidance recommends that the decision on whether to start treatment with Pradaxa should be made
German corporation, Boehringer Ingelheim, and the Californian firm, Gilead Sciences, have entered into a licensing agreement, under which Boehringer Ingelheim has given Gilead exclusive worldwide rights for the research, development and commercialisation of its novel non-catalytic site integrase inhibitors for HIV. This includes the lead compound BI 224436, which has been evaluated in a Phase
